XGN
Exagen IncNASDAQ
Healthcare • Diagnostics & Research
Factor tilt: Micro-Cap Blend
$5.81-23.55%
Close Nov 6, 2026
- Market cap
- $140.37M
- 1 month
- -28.9%
- 3 months
- -12.5%
- 1 year
- -43.8%
- 52-week range
- $2.65$9.59
- Dividend
- No dividends on record
- Short interest
- 4.9% of float673.9K shares · settled Oct 15, 2026 · -4.4% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $71.12M
- Net income
- -$18.92M
- Free cash flow
- -$7.59M
- Book value
- $12.22M
- Total debt
- $25.55M
- P/E
- —
- Price / sales
- 2×
- Price / book
- 11.5×
- FCF yield
- -5.4%
- Net margin
- -26.6%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Read more
The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
- Website
- exagen.com
- Headquarters
- Vista, CA, United States
- Employees
- 216
- Listed
- Sep 19, 2019
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 22, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 4, 2026 | $19.9M | +15.9% | 61.3% | -$1.7M | -$3.2M |
| Mar 2026filed May 11, 2026 | $17.3M | +11.7% | 59.0% | -$3.4M | -$4.0M |
| Dec 2025filed Mar 10, 2026 | $16.6M | +21.8% | 55.4% | -$5.0M | -$4.7M |
| Sep 2025filed Nov 4, 2025 | $17.2M | +37.9% | 58.4% | -$3.1M | -$7.1M |
| Jun 2025filed Jul 29, 2025 | $17.2M | +14.2% | 60.4% | -$2.6M | -$4.4M |
| Mar 2025filed May 5, 2025 | $15.5M | +7.5% | 58.9% | -$3.4M | -$3.8M |
| Dec 2024filed Mar 11, 2025 | $13.7M | -0.8% | 62.1% | -$3.4M | -$3.8M |
| Sep 2024filed Nov 12, 2024 | $12.5M | -6.8% | 55.8% | -$4.7M | -$5.0M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 10, 2026 | $66.6M | +19.7% | 58.3% | -$14.1M | -$20.0M |
| Dec 2024filed Mar 11, 2025 | $55.6M | +5.9% | 59.5% | -$13.6M | -$15.1M |
| Dec 2023filed Mar 18, 2024 | $52.5M | +15.3% | 56.1% | -$22.8M | -$23.7M |
| Dec 2022filed Mar 20, 2023 | $45.6M | -5.7% | 46.9% | -$46.1M | -$47.4M |
| Dec 2021filed Mar 22, 2022 | $48.3M | +15.1% | 57.4% | -$24.1M | -$26.9M |
| Dec 2020filed Mar 16, 2021 | $42.0M | +3.9% | 60.6% | -$15.2M | -$16.7M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched XGN. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
673,850 shares short
-30,784 shares (-4.4%) vs Sep 30, 2026
4.9% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
704,634 shares short
-95,710 shares (-12%) vs Sep 15, 2026
5.1% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
800,344 shares short
-63,694 shares (-7.4%) vs Aug 31, 2026
4.9% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
864,038 shares short
-76,394 shares (-8.1%) vs Aug 14, 2026
5.3% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
940,432 shares short
+36,556 shares (+4%) vs Jul 31, 2026
5.8% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
903,876 shares short
-75,104 shares (-7.7%) vs Jul 15, 2026
5.6% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind XGN’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if XGN is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
12 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Smart-money 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: neutral
Last trade: buy 18 days ago
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 8
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
Stored recent-activity label: neutral. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
57 filers reported a long position in XGN for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
64.1%
of the 7.9M shares 13-F filers reported
Moves vs Q1 2026
5 added4 trimmed
1 unchanged
Net shares held
+2.9%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | WEXFORD CAPITAL LP | $3.7M · 792.9K shares | 792.9K | Unchanged |
| 2 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | $3.1M · 675K shares | 675K | +15.4% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $2.8M · 612.8K shares | 612.8K | -9.7% |
| 4 | FourWorld Capital Management LLC | $2.8M · 596.5K shares | 596.5K | +35.6% |
| 5 | SILVERCREST ASSET MANAGEMENT GROUP LLC | $2.4M · 514.8K shares | 514.8K | -4.3% |
| 6 | KENNEDY CAPITAL MANAGEMENT LLC | $2.3M · 485K shares | 485K | -1.7% |
| 7 | Mink Brook Asset Management LLC | $2.2M · 475.9K shares | 475.9K | +29% |
| 8 | JANE STREET GROUP, LLC | $1.5M · 322.5K shares | 322.5K | +36.2% |
| 9 | ACADIAN ASSET MANAGEMENT LLC | $1.4M · 310.1K shares | 310.1K | -55% |
| 10 | First Eagle Investment Management, LLC | $1.4M · 307K shares | 307K | +145.1% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of XGN file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| May 27, 2026 | CIK 207583313G · passive | 5.3% |
| May 20, 2026 | Chernett Jorey13G · passive · amended | 9.9% |
Get the Full Analysis for XGN
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.